Table 1.

Patient Demographics [10,13,19,20,21,29,30].

	n	Age (years)	Height (Mean, cm)	Weight (Mean, kg)	Ethnicity	Concurrent Use of Hormonal Therapy	Reported Sexual Dysfunction	Previous Treatment for Sexual Dysfunction
Ito et al. RCT (2001)
	77	22–71	NR	NR	NR	NR	NR	6
Meston et al. RCT (2002)
	24	27–69	159.5	70.7	Caucasian (88%) Hispanic (4%) African American (4%) Asian (4%)	NR	NR	NR
Ito et al. RCT (2006)
Total	108	22–73	NR	NR	NR	ArginMax (n = 18) Placebo (n = 16)	NR	n = 12
Pre-menopausal	59	22–48	NR	NR	NR	NR	NR	n = 12
Perimenopausal	20	36–57	NR	NR	NR	3	NR	NR
Postmenopausal	29	42–73	NR	NR	NR	18	NR	NR
Bottari et al. RCT (2012)
	80	45–55	NR	NR	NR	Exclusion criteria	Moderate sexual dysfunction	NR
Bottari et al. NRCT (2013)
	100	37–45	NR	NR	NR	All women reported taking oral contraceptives	NR	NR
Stanislavov et al. RCT (2014)
	80	40–50	NR	NR	NR	Exclusion criteria	Moderate sexual dysfunction	NR
Cesarone et al. NRCT study (2019)
Pre-menopausal	67	40–50	NR	NR	NR	Exclusion criteria	Moderate sexual dysfunction	NR
Post-menopausal women	73	50–60	NR	NR	NR	Exclusion criteria	Moderate sexual dysfunction	NR

Abbreviations: NR: not reported; NRCT: nonrandomized controlled trial; RCT: randomized controlled trial.